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A B S T R A C T
The delivery of peptide drugs to the brain is challenging, principally due to the blood brain barrier and the low
metabolic stability of peptides. Exclusive delivery to the brain with no peripheral exposure has hitherto not been
demonstrated with brain quantification data. Here we show that polymer nanoparticles encapsulating leucine5-
enkephalin hydrochloride (LENK) are able to transport LENK exclusively to the brain via the intranasal route,
with no peripheral exposure and nanoparticle localisation is observed within the brain parenchyma. Animals
dosed with LENK nanoparticles (NM0127) showed a strong anti-nociceptive response in multiple assays of
evoked and on going pain whereas animals dosed intranasally with LENK alone were unresponsive. Animals did
not develop tolerance to the anti-hyperalgesic activity of NM0127 and NM0127 was active in morphine tolerant
animals. A microparticulate formulation of clustered nanoparticles was prepared to satisfy regulatory require-
ments for nasal dosage forms and the polymer nanoparticles alone were found to be biocompatible, via the nasal
route, on chronic dosing.
1. Introduction
The delivery of peptides to the brain is challenging, not merely
because of the blood brain barrier but also because peptides have a very
short plasma half life and are frequently not detected in the plasma on
intravenous administration [1]. The intranasal to brain route of ad-
ministration has emerged as an interesting route for the administration
of compounds directly into the brain [2] even though the dose (100 μL
or 25 mg) is a limitation. Here we show that the use of an intranasal
nanoparticle delivery system enables the delivery of a metabolically
unstable [3], δ selective opioid receptor (DOR) [4][5] agonist, leucine5-
enkephalin hydrochloride (LENK), directly and exclusively to the brain.
The δ selectivity has been well studied by Toll and others [5] using
cloned human μ, δ and κ receptors in Chinese Hamster Ovary (CHO)
cells with EC50 values, in 35SGTPγS binding assays, of 25.5 ± 0.8 nM
and 1.35 ± 0.2 nM for μ-CHO and δ-CHO cell membranes respectively.
Similar results were obtained with guinea pig brain membranes with Ki
values of 21.7 ± 1.4 nm and 1.6 ± 0.5 nm obtained when using the μ
(3H DAMGO) and δ (3H DPDPE) selective agonists respectively [5].
DORs reside in the cerebral cortex, putamen, caudate nucleus, nucleus
accumbens and hippocampus of humans [6] and hence exclusive brain
delivery, via a non-parenteral route of administration, enables LENK to
be considered as a potential analgesic. Chronic pain affects 19% of
European adults, with nearly half being poorly managed by current
therapies and with devastating consequences on their quality of life [7].
While neuropathic pain (diabetic, post herpetic or human im-
munodeficiency virus related) affects 6 million patients in the seven
major markets (United States, Japan, France, Germany, Italy, Spain and
the UK), only 25% of these patients experience pain relief with the
current approved medicines [8]. Furthermore breakthrough pain is
highly prevalent in analgesic treated cancer patients with one study
reporting prevalence rates of 74% [9] and 45% of the patients studied
were unable to predict the onset of excruciating breakthrough pain [9].
Breakthrough pain requires remedies with a rapid onset of action.
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Opiates acting predominantly at mu opioid receptors (MORs) have been
used to treat both chronic and acute pain for thousands of years [10]
although the side effects of these medicines (constipation, nausea,
drowsiness, dependence and respiratory depression) [11] often limit
their use. The endogenous opioids, i.e. the enkephalins, have been
studied but not developed as drugs, due to their rapid enzymatic de-
gradation and poor brain permeation [12–14], despite the use of var-
ious penetration enhancers [15,16]. However enkephalinase inhibitors
have been trialled in the clinic [17].
The nose to brain route has been advocated as a delivery route for
labile and high molecular weight drugs to the brain in humans [2,18],
as drugs can access the brain directly through the olfactory neurons as
well as avoid first pass liver metabolism and gastrointestinal degrada-
tion. However such intranasal dosage forms must also avoid the de-
gradative enzymes (e.g. carboxypeptidases and cytochrome P450)
present in the human nasal cavity [19,20]. Administration of drugs to
the nasal cavity is also a means of achieving systemic exposure due to
the highly vascularised respiratory epithelium, which enables absorp-
tion of drugs into the blood through paracellular or transcellular epi-
thelial and endothelial pathways and there are products on the market
that are delivered nasally to achieve systemic exposure, including
peptides [21]. While delivery to only the brain via the intranasal route,
has been inferred by others [2], here we demonstrate exclusive delivery
of a low molecular weight and metabolically labile peptide, leucine5-
enkephalin (Molecular weight = 556 Da), to the brain on intranasal
administration and when formulated as a nanoparticle with no per-
ipheral exposure or activity. The peptide is of pharmaceutical interest
as a possible pain therapeutic.
2. Materials and methods
2.1. Materials
All reagents and chemicals were obtained from Sigma Aldrich
Chemical Co, UK, unless otherwise stated. All solvents and acids were
obtained from Fisher Scientific, Loughborough, UK. Dialysis mem-
branes were purchased from Medicell International Ltd., UK. Deuterium
oxide, Methanol-d6 and deuterated palmitic acid (palmitic acid-d31)
were obtained from Cambridge Isotope Laboratories Inc. UK. Leucine5-
Enkephalin hydrochloride was obtained from CELTEK Bioscience, USA.
Morphine sulphate and Isoflurane were purchased from Centaur
Services Ltd., UK. Water for injection and saline were obtained from
AAH pharmaceuticals Ltd., Coventry, UK. Naloxone hydrochloride MP
Biomedicals, USA. Nanomerics' Molecular Envelope Technology (GCPQ
– N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-gly-
colchitosan) was obtained from Nanomerics Ltd. All reagents and che-
micals were used without further purification and were ≥99% purity.
Animals were purchased from Harlan, UK or Harlan, USA (CPP animals
only) and PE10 tubing was purchased from Smiths Medical, UK.
2.2. Methods
2.2.1. NM0127 nanoparticles
NM0127 nanoparticles were prepared from GCPQ (N-palmitoyl-N-
monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan,
Mw= 18.6 ± 4.6 kDa, Mw/Mn= 1.033 ± 0.027, mole% palmitoy-
lation = 15 ± 1.3, mole% quaternary ammonium groups = 8 ± 0.8)
and LENK by vortexing for 5 min in water for injection BP, the pH ad-
justed to pH= 5.8 with NaOH (1 M) prior to probe sonicating (Qsonica,
UK) with the instrument set at 30% of its maximum output for 10 min on
ice. For the CFA and CPP studies the GCPQ had the following char-
acteristics: Mw= 18.0 ± 3.7 kDa, Mw/Mn= 1.029 ± 0.023, mole%
palmitoylation = 16 ± 3.6, mole% quaternary ammonium
groups = 10 ± 2.2. NM0127 formulations for intranasal, intravenous
and oral use had a GCPQ, LENK weight ratio of 1, 2.3 and 5 respectively.
Particle sizing was carried out with a Malvern Zetasizer 3000HS
(Malvern Instruments, UK) at 25 °C and a wavelength of 633 nm with
data analysed using the Contin method.
NM0127 was imaged by transmission electron microscopy (TEM). A
drop of NM0127 was placed on Formvar/Carbon Coated Grid
(F1961100 3.05 mm, Mesh 300, Tab Labs Ltd., UK), stained (aqueous
Uranyl Acetate - 1% w/v) and imaged (FE1 CM120 BioTwin Microscope
equipped with an AMT digital camera, Thermofisher Scientific, UK).
2.2.2. Peptide analysis
LENK analysis was performed on an Agilent high performance liquid
chromatography (HPLC) system (Agilent Technologies, UK) consisting
of a binary pump (1220 Infinity LC Gradient System VL) equipped with
a variable wavelength UV detector (λ= 214 nm) and an Onyx mono-
lithic C18 column (5 μm particle size, 4.6 mm× 10 mm) with a C18
guard column (Phenomenex, UK). Mobile phase = water, acetonitrile,
trifluoroacetic acid (81.98: 18: 0.02), flow rate = 1 mL min−1, column
temperature = 30 °C, injection volume = 10 μL, LENK retention
time = 6.6 min, calibration curve for quantification (y = 14.6 ± 1.1,
r2 = 0.999 ± 0.002, n = 11 separate experiments), lower limit of
quantification = 5 μg mL−1. Data analysis was via Agilent
Chemstation. NM0127 formulations were diluted in mobile phase, fil-
tered (0.22 μm) and the filtrate analysed by HPLC.
2.2.3. NM0127 Nano-in-micro formulations
NM0127 Nano-in-Micro formulations were prepared from LENK and
GCPQ (Mw= 11.2 kDa, Mw/Mn = 1.01, Mole% palmitoylation = 23,
Mole% quaternary ammonium groups = 12) in distilled water (20 mL)
at a total solid concentration of 10% w/v and a GCPQ, LENK ratio of
1 g g−1. The suspension was subjected to high pressure homogenisation
(EmulsiFlex C5, Avestin, Germany, 1 cycle at 18000 Psi) and the re-
sulting nanoparticles spray dried to give NM0127 nano-in-micro par-
ticles (Büchi Nano Spray Dryer B290 equipped with ultrasonics, Büchi
Labortechnik AG, Switzerland, inlet temperature = 180 °C, outlet
temperature = 120 °C, nozzle temperature = 60 °C, aspirator flow
rate = 36 m3 h−1, spray rate = 1 mL min−1, power at the noz-
zle = 1.8 watts). Particle sizing was via an Helos sizer (Sympatec
GmbH, Germany), peptide analysis by HPLC and particle imaging
achieved using an FEI Quanta 200 F scanning electron microscope
(ThermoFisher Scientific, The Netherlands).
X-ray diffraction analyses were carried out using a Rigaku MiniFlex
600 diffractometer (Rigaku, UK) with a voltage of 40 kV, a current of
15 mA. Patterns were obtained using a step width of 0.02 deg. with a
detector resolution in 2θ (diffraction angle) between 2 deg. and 60 deg.
NM0127 microparticles (4 mg) were dispersed in water (0.1 mL)
and gently shaken for 10 min to regenerate the nanoparticles and the
nanoparticles imaged by TEM.
2.2.4. Animals
Male Sprague Dawley rats (weight = 200–275 g for the behavioural
studies and 130–170 g for the pharmacokinetics studies) were housed
four per cage in an air conditioned unit (20–22 °C, 50–60% humidity)
and allowed free access to standard rodent chow and water. Lighting
was controlled on a twelve-hour cycle (on at 07.00 h and out at
19.00 h). Animals were habituated for 7 days prior to experimentation
and acclimatised to the procedure room for 1 h prior to testing. All
protocols were conducted under a UK Home Office licence and ap-
proved by a local ethics committee with the exception of CPP studies
which were reviewed and approved by the Institutional Animal Care
and Use Committee of the University of New England, and were carried
out in compliance National Institutes of Health guidelines. Animals
were randomised prior to all experiments using the Latin Square
method (behavioural studies) or by weight (pharmacokinetics and
imaging studies) and all behavioural experiments assessed by an op-
erator blinded to the treatment by assigning the animals codes and the
dosing then carried out in order of the codes. The data analysis also
done with code identifiers or by a separate operator. This was except for
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the CPP studies, which were video monitored. Sample sizes were chosen
based on either power calculations after a pilot study to determine the
standard deviation (all behavioural experiments) or after a pilot study
(pharmacokinetics experiments).
2.2.5. Anti-nociception hot plate test
Prior to dosing rats were placed on a hot plate to ascertain the
baseline levels of residency prior to an escape attempt (a jump or a lick
of the paw) and for a maximum time of 30 s. Rats were dosed with
various intravenous and oral doses of NM0127 and control animals
dosed the relevant vehicle.
At various intervals after dosing, rats were then placed on the hot
plate for a maximum of 30 s and the time to escape attempt recorded.
Anti-nociception was recorded as the difference between the hotplate
residency time before and after dosing.
2.2.6. Intranasal dosing and dose response analysis
For the Complete Freund's Adjuvant and conditioned placement
preference studies, rats were intranasally administered with water for
injection, intranasal LENK or various doses of NM0127. Animals were
briefly anesthetised with isoflurane and intranasally administered the
formulation using an insulin syringe attached to PE10 tubing (15 mm),
the tubing was inserted into one of nares [22].
2.2.7. Complete Freund's adjuvant induced tactile hypersensitivity
Rats received an intraplantar injection of Complete Freund's ad-
juvant (CFA). CFA induced hind paw oedema and tactile hypersensi-
tivity were evaluated 24 h after the CFA injection [23]. Rats were in-
dividually placed on an elevated plastic mesh (0.5 cm2 perforations) in
a clear plastic cage. Two habituations to the evaluation chambers for at
least 5 min duration each were performed on two different days. A
baseline measurement was taken on test day pre-CFA. Tactile hy-
persensitivity was assessed by the sensitivity to the application of von
Frey filaments (Ugo Basile, Italy). The von Frey filaments (1.4, 2, 4, 6,
8, 10, 15, 26 g) were presented perpendicularly to the plantar surface of
the injected paw in ascending order, and held in this position for 5 s
with enough force to cause a slight bend in the filament. Positive re-
sponses, included an abrupt withdrawal of the hind paw or a flinching
on application of the hair. Once a positive withdrawal response was
established, the paw was retested, starting with the next descending
von Frey hair until no response occurred. The lowest amount of force
required to elicit a response was recorded as the paw withdrawal force
(g) [24].
Tactile hypersensitivity was defined as a significant decrease in
withdrawal thresholds to von Frey filament application.
To test the formulation effects on tactile hypersensitivity, rats were
evaluated for thresholds 24 h after CFA injection; they were then ran-
domised according to their threshold values and administered with
formulations. Once the evaluation was complete, rats were returned to
their home cage for 3 days and then thresholds were reassessed on day
5 post the CFA injection.
2.2.8. Central and peripheral contributions to anti-hyperalgesia
24 h after a CFA injection, non-selective opioid antagonists (na-
loxone hydrochloride and naloxone methiodide) were administered
subcutaneously (to enable unfettered access of naloxone and naloxone
methiodide to the central and peripheral opioid receptors) and con-
comitantly with intranasal NM0127 in water and paw withdrawal
thresholds assessed.
2.2.9. Analgesic tolerance and analgesic cross tolerance to morphine
Intranasal NM0127 in water was administered and the paw with-
drawal threshold assessed. Subsequently the same dose of NM0127 was
administered intranasally to the same animals twice a day (9 am, 2 pm)
for 4 days. The paw withdrawal thresholds were reassessed after the
administration of a final dose on day 5. Morphine sulphate was
administered subcutaneously as a positive control.
To assess the development of cross tolerance to morphine, sub-
cutaneous morphine sulphate was administered to two groups of ani-
mals and the paw withdrawal thresholds were assessed. Subsequently
both groups of animals were administered morphine sulphate twice a
day (9 am and 2 pm) for 4 days and on Day 5, intranasal NM0127 in
water was administered to one group of morphine dosed animals, while
subcutaneous morphine sulphate was administered to the second group
of morphine dosed animals, and the paw withdrawal threshold re-as-
sessed for both groups. Subcutaneous and intranasal PBS were ad-
ministered to control animals on Days 1 and 5 respectively.
2.2.10. Spinal nerve ligation (SNL) and conditioned placement preference
(CPP) studies
Spinal nerve ligation (SNL) at L5 and L6 was induced using the
procedure of Kim and Chung [25]. Sprague Dawley rats were an-
esthetized with 2% isoflurane. A 3 cm longitudinal incision, 5 mm lat-
eral from the midline was made at the lower lumber and sacral levels.
The location of the incision is determined by the position of the L5
spinous process. Connective tissues, remaining muscle and L6 spinous
processes were removed, the L5 and L6 spinal nerves freed from the
adjacent structure, and the nerves tightly ligated with 4–0 silk suture.
Haemostasis was confirmed, the muscles sutured in layers and the
wound closed. Sham control rats underwent the same operation and
handling as the experimental animals but without actual ligation.
7 days post-surgery the absence and presence of hypersensitivity was
confirmed in Sham and SNL animals respectively by von Frey filaments
as described above.
Conditioned place preference (CPP) was performed using a mod-
ification of the single trial conditioning procedure previously described
[26,27]. On day 13 post surgery rats underwent a 1 day habituation in
which they were placed in the CPP boxes and allowed to explore all
chambers. Behaviour was recorded and analysed to verify that no
chamber bias existed to the conditioning chambers, as defined by
spending< 180 s or> 720 s in one of the chambers. Animals ex-
hibiting a chamber bias (< 3% of total animals tested for CPP, i.e. 1
animal) were removed from the study. The following day (conditioning
day), all rats (Sham and SNL) received an intranasal dose of the vehicle,
under short term isoflurane anaesthesia and were immediately (within
2 min) confined to the appropriate pairing chamber for 30 min in the
morning. Animals were removed and placed in their home cages for 4 h.
For the afternoon session animals received intranasal NM0127 in water
under short term isoflurane anaesthesia and were immediately (within
2 min) confined to the opposite chamber for 30 min. On the test day,
20 h following the afternoon pairing, rats were placed in the CPP box
with access to all chambers and their behaviour video recorded for
15 min. Significantly increased post-conditioning time spent in the
drug-paired chamber, as compared to pre-conditioning time, indicates a
CPP. Decreased post-conditioning time spent in the drug paired
chamber, as compared to the pre-conditioning time, indicates condi-
tioned place aversion. No change between the time spent in the drug-
paired chamber, as compared to pre-conditioning time, indicates no
conditioned place preference or aversion.
2.2.11. Pharmacokinetics
Male Sprague Dawley rats weighing 145–180 g (n = 6) were briefly
anesthetised with isoflurane and intranasally administered either no
treatment, LENK or NM0127 in water.
At various time points, animals were killed with an intraperitoneal
overdose of pentobarbital and the brains removed, separated from the
olfactory bulb and cerebellum and the cerebrum washed in phosphate
buffered saline (PBS, pH = 7.4). Cerebrum and olfactory bulb tissues
were immediately snap frozen in liquid Nitrogen and analysed on the
same day of sampling. After the pentobarbital overdose, blood samples
were also taken by cardiac puncture and collected into EDTA vacutainer
tubes. Protease inhibitor cocktail (10 μL, Sigma, UK) was added to each
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tube and the tubes inverted. Plasma was separated by centrifugation
(2000g× 15 min, 4 °C) and plasma samples were stored at −80 °C
until analyses could be performed on them.
An aliquot of the plasma sample (500 μL) was mixed with an equal
volume of the extraction medium (1 M acetic acid, 0.02 M HCL, 1%
mercaptoethanol) and to this was added the internal standard (dalargin,
10 μg mL−1, 10 μL) and protease inhibitor cocktail (10 μL). The plasma
samples were centrifuged (6800g for 30 min at 4 °C) and to the super-
natant was added trichloroacetic acid (TCA, 50%w/v, 200 μL) and the
resulting mixture centrifuged again (6800g for 30 min at 4 °C). The
supernatant was then extracted with diethyl ether (3 × 1 mL each
time) and the aqueous layer freeze dried. The freeze dried residue was
reconstituted in formic acid (0.1% w/v, 200 μL), filtered (0.2 μm) and
the filtrate analysed by LC-MS.
Plasma calibration curve standards were prepared, by extracting
spiked plasma (500 μL), which had been diluted with an equal volume of
extraction medium (LENK= 1–100 ng mL−1, dalargin = 100 ng mL−1,
y = 51.19x + 720.89, r2 = 0.97).
To every 1.3 g of fresh cerebrum sample was added 13 mL of TCA
(50% w/v) followed by the addition of protease inhibitor cocktail
(1 mL). Brain samples were then homogenised and aliquots (1 mL) of
this homogenate spiked with dalargin (10 μg mL−1, 10 μL), centrifuged
(10,000g× 30 min, 4 °C) and to an aliquot of the supernatant (800 μL)
was added TCA (50% w/v, 160 μL). The mixture was centrifuged again
(10,000g for 30 min at 4 °C) and the supernatant extracted with diethyl
ether (3 × 1 volume). An aliquot of the resulting aqueous phase
(500 μL) was freeze-dried. The freeze-dried sample was reconstituted in
formic acid (0.1% v/v, 200 μL) and analysed by LC-MS.
For the brain calibration curve, to each 1.3 g of tissue was added to
13 mL of TCA (50% v/v), followed by protease inhibitor cocktail
(1 mL); the brain samples homogenised and aliquots (1 mL) used to
construct a standard curve after extraction as detailed above
(LENK = 1–1000 ng mL−1, dalargin = 100 ng mL−1, y = 0.0046x
+ 0.232, r2 = 0.998).
Fresh olfactory bulb samples were weighed and TCA (50% v/v,
2 mL) added followed by the protease inhibitor cocktail (100 μL). The
samples were then homogenised and to aliquots of this homogenate
(1 mL) were added dalargin (10 μg mL−1, 10 μL), the sample cen-
trifuged (10,000g× 30 min, 4 °C) and to the supernatant (800 μL)
added TCA (50% v/v, 160 μL). The supernatant was then again cen-
trifuged (10,000g× 30 min, 4 °C) and the resulting supernatant ex-
tracted with diethyl ether (3 × 1 volume). An aliquot of the resulting
aqueous phase (500 μL) was freeze-dried. The freeze-dried sample was
reconstituted in formic acid (0.1%, 200 μL) and analysed by LC - MS.
Olfactory bulb calibration standards were prepared by adding 6 mL
of TCA (50% v/v) to 150 mg of tissue, followed by the addition protease
inhibitor cocktail (100 μL). The samples were then homogenised and
aliquots (1 mL) used to construct a standard curve after extraction as
detailed above (LENK = 1–600 ng g−1, dalargin = 100 ng mL−1,
y = 0.0265x + 0.176, r2 = 0.995).
LC-MS/MS analysis was carried out using an Agilent 1260 infinity
LC system (Agilent Technologies, Berkshire, UK) interfaced directly
with Agilent 6460 triple quadrupole. Samples were separated on a re-
verse phase C18 Zorbax column (2.1 × 50 mm, 5 μm particle size) in a
gradient mode with formic acid (FA, 0.1% w/v), acetonitrile: t0 = 95%
FA, t5 = 70% FA, t5.5 = 5% FA, t6.5 = 5% FA, t7 = 95% FA. Mobile
phase flow rate = 0.3 mL min−1, column temperature = 30 °C, injec-
tion volume = 10 μL, run time = 10 min. The retention times for da-
largin and LENK were 4.6 min, 5.6 min respectively. The samples were
ionized by electrospray ionization (ESI) in a positive ion mode. The
electrospray parameters were as follows: electrospray capillary
voltage = 3.5 kV, source temperature = 300 °C, ESI source = ni-
trogen, gas flow = 5 L min−1, ion detection = Multiple Reaction
Monitoring mode (Table 1).
2.2.12. Multiphoton microscopy
Deuterated GCPQ (dGCPQ) was supplied by Nanomerics Ltd. and
dGCPQ nanoparticles synthesised as previously described [15]. Rats
were intranasally dosed with dGCPQ and were subsequently killed at
various time points, brains harvested and stored in neutral buffered
formalin [(formaldehyde - 4% v/v, sodium phosphate monobasic –
0.4% w/v, sodium phosphate dibasic – 0.65% w/v) 60 mL]. All samples
for multiphoton imaging were prepared as described previously and
imaging carried out as described previously [15,28]. Nuclear mem-
branes were identified as they were less lipid rich than the cell cyto-
plasm and appear darker in the image. Myelin sheaths around the
neurons are lipid rich and appear brighter in the image and the cell
membrane is lipid rich and appears brighter in the image.
2.2.13. Intranasal GCPQ good laboratory practice toxicology studies
Groups of male (n = 10) and female (n = 10) Sprague Dawley rats
(starting weight 200–230 g for females and 320–340 g for males) were
intranasally dosed (0.2 mL kg−1/day dosed in 4 separate doses/day)
with GCPQ nanoparticles in water for injection daily for 28 days and at
three dose levels: a) 12 mg kg−1, b) 18 mg kg−1 and c) 24 mg kg−1.
Groups of male (n = 10) and female (n = 10) Sprague Dawley rats
were administered water for injection at the same dose volume as the
test animals. The doses were given using a micropipette with attached
appropriately sized plastic tip. All animals received 4 instillations into
each nostril of either the control or the test item for a total of 0.2 mL on
each treatment day. During dosing, the rats were held with their head in
a vertical position. The micropipette was kept approximately 0.5 mm
into the first nostril and the 0.025 mL drop of formulation was instilled.
Immediately afterwards the second nostril was instilled. The animal
was kept vertical for a few seconds to allow the formulation to dis-
appear into the nose and then put back in its cage. Animals were
weighed daily, food consumption monitored and examined for general
condition prior to and after each dose with the eyes monitored peri-
odically after the application of a mydriatic agent (1% Tropicamide).
Blood was collected from the orbital sinus under isoflurane anaesthesia
using a capillary tube and blood chemistry and haematology para-
meters determined. Urine was collected over an 18 h period, where the
animals had no access to food but access to water and urine analysis
carried out. At the end of the study, animals were killed using carbon
dioxide, were subject to a full necropsy examination and histology
samples examined.
2.2.14. Statistical analysis
Data were analysed by one or two-way analysis of variance
(ANOVA) followed by Bonferroni post hoc test (equal variance) and
Greenhouse-Geisser correction with Games Howell post hoc test if there
was unequal variance. All statistical analyses were performed using
SPSS (IBM, UK) and Graphpad Prism (GraphPad Inc., USA). P va-
lues < 0.05 were considered significant. For the conditioned place-
ment preference experiments, data were analysed using a 2-factor
analysis of variance (ANOVA: pre vs post conditioning by treatment
group). Post hoc analysis was performed using Bonferroni tests.
2.2.15. Data and materials
Data and materials are available to readers by writing to the cor-
responding author.
3. Results and discussion
There is undoubtedly an unmet clinical need for efficacious an-
algesics. The current opioids are efficacious in the treatment of severe
pain but are limited by the prevalence and severity of their side effects
[11]. An endogenous peptide with analgesic properties and minimal
side effects could certainly provide benefit to patients suffering from
severe pain. However the delivery of peptides to the brain is not en-
tirely without its own challenges. Our work demonstrates that we have
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solved this peptide delivery problem. We tested the hypothesis that the
encapsulation of an endogenous peptide with analgesic activity [29],
within nanoparticles (that may be further formulated as micro-
particles), would lead to peptide brain delivery and analgesia.
LENK is formulated with N-palmitoyl-N-monomethyl-N,N-dimethyl-
N,N,N-trimethyl-6-O-glycolchitosan (GCPQ) into a mixture of single
30 nm–40 nm nanoparticles and aggregated 100–200 nm nanoparticles
(NM0127). The nanoparticles, in turn, are formulated into microparticles
(volume mean diameter = 22.2 ± 0.96 μm, D10 = 11.07 ± 0.82 μm,
D50 = 20.12 ± 1.14 μm, D90 = 35.38 ± 1.48 μm) as required for
European intranasal formulations [30] (Fig. 1a and b). GCPQ preclinical
toxicology studies produced an intranasal 28 day repeat dose no ob-
served adverse effect level (NOAEL) of 18 mg kg−1/day with minimal
nasal cavity mucosal cell changes seen at 24 mg kg−1 [Supplementary
Information (SI) SI Table 1]. The formulation is amorphous (SI Fig. 1a),
stable for at least 90 days at room temperature (SI Fig. 1b–d) and delivers
the peptide into the olfactory bulb and brain (Fig. 1c and d) on intranasal
administration. Peptide brain delivery is mediated by the transport of the
GCPQ nanoparticles into the olfactory neurons and further to the deeper
brain regions of the thalamus and cortex (Fig. 2a–f, SI Fig. 2a and b), as
imaged by Coherent Anti-Stokes Raman Scattering (CARS) microscopy
[31] (with three animals sampled at all time points) and discussed below.
Lochhead and others [32] have described the perivascular transport of
fluorescent dextran to deep areas of the brain and their work provides
evidence of a nose to brain transport pathway involving trigeminal
neurons and perivascular arterial pathways. Our data supports the
perivascular route of transport of these particles as perivascular located
particles are indeed seen in the olfactory bulb (2b, yellow arrow) and
cortex (2d, yellow arrow) CARS images, with red blood cells arrowed in
white to locate the blood vessels. In our nanoparticle study, while par-
ticle entry to the olfactory neurons was shown in CARS images (Fig. 2a,
yellow arrows – bottom of the image), we could not confirm particle
transport via the respiratory epithelia/ trigeminal nerve pathway as is
seen with the application of substances in solution [32,33].
There is no plasma exposure to the peptide when six animals were
sampled at each time point (0.25, 0.5, 1 and 1.5 h) and this may be
attributed to the very short peptide plasma half-life of 5–15 min [12].
Thus our data indicate that the intranasal particle approach allows
exclusive delivery of this labile peptide to the brain. The nasal capillary
pore size has been recently determined by Kumar and others [34] as:
Table 1
LC-MS/MS analytical conditions.
Name Precursor ion Product ion Dwell time Frag (V) CE (V) Cell Acc (V) Polarity
Dalargin 726 120 200 175 70 4 Positive
LENK 556 278.1 200 150 20 4 Positive
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Fig. 1. NM0127 formulation morphology (a and b) and kinetics after nose-to-brain administration in male Sprague Dawley (SD) rats (c and d).
a) Scanning electron microscopy image of freshly prepared NM0127 microparticles (GCPQ, LENK ratio = 1: 1 g g−1).
b) Transmission electron microscopy image of NM0127 nanoparticles reconstituted from microparticles (a) in water (LENK concentration = 30 mg mL−1).
c and d) Concentration of LENK (mean ± s.d. n = 6) in the olfactory bulb (c) and cerebrum (d) following the administration of LENK (23 mg Kg−1, 50 mg mL−1) in NM0127
nanoparticles (LENK, GCPQ ratio = 1 g g−1) or as the peptide alone. LENK was not detected in the plasma (n = 6 per time point) at any of the time points studied (15, 30, 60 and
120 min). **** = statistically significant differences between both groups (p < 0.0001). Images in Fig. 1a and b are representative images from 3 experiments. Data in Fig. 1c and d are
representative data from 3 replicated experiments.
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13–17 nm in the nasal respiratory vasculature and the olfactory bulb
capillary pore size has been determined as< 10 nm in the olfactory
bulb vasculature. This means that the transport of these 30–200 nm
nanoparticles from the nasal cavity to the peripheral circulation and
from the olfactory bulb to the peripheral circulation would be highly
restricted, even though Nanomerics' MET nanoparticles are known to be
taken up by epithelial cells [35]. However particles are seen on the
abluminal surface of the thalamus blood vessels (Fig. 2d). The presence
of particles in the abluminal surface of the thalamus blood vessels in-
dicates that particle brain to blood transport in the thalamus is possible
and we speculate that this is a probable route of particle/ polymer
excretion.
Brain Cmax levels with nanoparticulate LENK were at 280 nM
30 min after dosing and are thus well in excess of the LENK kD values of
5 nM [36] and brain levels fell to 61 nM at the 90 min time point
(Fig. 1d). However it must be stated that our analytical method did not
allow us to distinguish between bound and free peptide. However un-
equivocal anti-nociceptive responses from multiple animal pain models
does suggest that the peptide is available to bind to its receptors in the
brain.
Kumar et al. reported anti-nociceptive data, with intranasal LENK
trimethylchitosan formulations [37]. However no pharmacokinetics
data were reported in this earlier study, and our data supplies crucial
mechanistic detail in support of this earlier report.
Animal behavioural data demonstrate that NM0127 reverses hy-
persensitivity in the CFA model of inflammation-induced tactile hy-
persensitivity (Fig. 3a-f,) and produces relief of on going pain in a nerve
injury model of neuropathic pain (Fig. 3g–h). The baseline paw with-
drawal threshold in the CFA model, using von Frey filaments, ranged
from 22.3 ± 5.7 to 26.0 ± 0 g, reducing to a range of 2.9 ± 1.2 to
20 µm
20 µm
a b
c d
e f
10 µm
20 µm
5 µm
Fig. 2. Coherent Anti-Stokes Raman Spectroscopy (CARS)
imaging of deuterated GCPQ (dGCPQ) nanoparticles in the
brain following the intranasal administration in male SD
rats (8.7 mg kg−1, 40 mg mL−1). Epi-detected dGCPQ
CARS signal from the unique CD stretch (pump and Stokes
tuned to excite 2100 cm−1) is shown in green (also yellow
arrows), while the non-specific counterstaining signal from
the CH stretch (pump and Stokes tuned to excite
2845 cm−1) appears in red. White dashed arrows highlight
red blood cells within the blood vessels, while white dashed
lines surround the edge of the nuclei. The dGCPQ signal is
seen: a) in olfactory bulb neuritis in the nerve layer 5 min
after dosing, b) in the olfactory bulb perivascular space
240 min after dosing, c) in the thalamus parenchyma
60 min after dosing (the cell membrane indicated by the
dotted yellow line), d) the thalamus abluminal surface of
the blood vessels and within the thalamus neurons 240 min
after dosing, e) and in the perivascular space of the cortex
60 min after dosing (the edge of the blood vessel is deli-
neated by a dashed green line and cross sections of neurons
are seen at the top – y plane - of the image). f) No dGCPQ
signal was seen in the basal ganglia 5 min after dosing. Data
in Fig. 2 are representative images from 2 experiments, each
comprising 3 animals at the relevant time points. (For in-
terpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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3.7 ± 1.5 g 24 h after the intraplantar injection of CFA (0.1 mL).
5 days after CFA dosing, the baseline paw withdrawal threshold ranged
from 4.3 ± 0.3 to 5.7 ± 0.3 g. The baseline paw withdrawal thresh-
olds, using von Frey filaments, for the sham and spinal ligation animals
were 13.68 ± 0.72 g and 6.00 ± 0.82 g respectively.
Intranasal delivery of LENK encapsulated in GCPQ particles
(NM0127) at a LENK dose of 7.5 mg kg−1 produced full reversal of
CFA-induced tactile hypersensitivity. NM0127 reversal of CFA induced
tactile hypersensitivity was only observed at LENK doses of 7.5 and
15 mg kg−1 (Fig. 3a–j) and not at a LENK dose of 3.5 mg kg−1
(Fig. 3a). Notably, intranasal administration of the LENK peptide alone
is pharmacologically ineffective (Fig. 3a).
Although LENK is detected in the olfactory bulb when administered
in solution (Fig. 1c), it is barely delivered to the brain when not en-
capsulated in nanoparticles (Fig. 1d), demonstrating that the nano-
particles facilitate the brain distribution to the thalamus and cortex,
possibly via brain perivascular pathways [32] (Fig. 2b and e). The na-
noparticles are thus instrumental in delivering the peptide to the brain.
The polymer used to make the nanoparticles normally confers a positive
surface charge to the nanoparticles and the particles are known to stick
to and integrate into mucosal surfaces [38], which are likely to be
present in the nasal cavity and we speculate that the mucointegration
may enhance the residence time of the nanoparticulate peptide in the
nares. This mucointegration would contribute to the pharmacody-
namics effects observed. Intravenous LENK alone is also incapable of
mediating an anti-nociceptive response (SI Fig. S1e) with only in-
travenous NM0127 being active. These observations indicate pharma-
cological activity is only obtained with the nanoparticle formulation
and is not obtained with the peptide alone. The NM0127 reversal of
CFA – induced tactile hypersensitivity is blocked by the opiate receptor
antagonist naloxone but not by the peripherally restricted [39] qua-
ternary ammonium inhibitor - naloxone methiodide (Fig. 3b). When
this data is viewed in combination with the lack of peripheral exposure
to LENK, we conclude that intranasal GCPQ nanoparticles may be used
to deliver LENK exclusively to the brain. By the 3 h time point naloxone
was no longer active (Fig. 3b) due presumably to its short plasma half-
life of 30–40 min in rats [40] and the anti-nociceptive activity of
NM0127 is restored.
While demonstrating the delivery potential of the nanoparticle
formulation is important, NM0127 also exhibits some potentially
Fig. 3. Anti-hyperalgesic effects (mean ± sem) in male SD rats against evoked stimuli in a model of chronic inflammatory pain (CFA, a–f, n = 6) and against on going neuropathic pain
in a conditioned placement preference model with spinal nerve ligation (SNL, i–j, n = 13–18). Evaluation parameters are kept constant throughout unless specified and LENK for-
mulations were dosed at a pH of 5.8. Data in Fig. 3 is representative data from at least two replicated experiments. Statistically significant differences are given as: *** = p < 0.001,
** = p < 0.01, * = p < 0.05.
a) Hyperalgesia is assessed using response to pressure exerted with graded von Frey filaments before and 24 h after intraplantar injection of CFA (0.1 mL) in the hind paw.
NM0127 = LENK given as GCPQ, LENK (ratio = 1 g g−1, 7.5 mg kg−1, 30 mg mL−1), NM0127 Low = LENK given as GCPQ, LENK (ratio = 1 g g−1, 3.5 mg kg−1, 14 mg mL−1),
LENK = LENK solution (7.5 mg kg−1), Water = water control (all volumes 0.25 mL kg−1). Statistically significant differences between the NM0127 group and other groups were as
follows: vs water (*** at 20, 40, 90, 120, 180 min; ** at 60, 240 min), vs LENK solution (** at 20, 40, 240 min; * at 90, 120, 180 min), vs NM0127 Low (** at 20 min, * at 40, 120,
240 min). The NM0127 Low group was not significantly different from the water group. Similar responses to the treatment and control formulations were recorded on Day 5 (data not
shown).
b) Peripheral and central contributions to the anti-hyperalgesic effect of intranasal NM0127 were evaluated by comparing the intranasal water control group with intranasal NM0127 at a
dose of 7.5 mg kg−1 combined with a concomitant subcutaneous injection (0.46 mL kg−1) of either naloxone (Nal, 7.3 mg kg−1), naloxone methiodide (NalMeth, 10 mg kg−1), or water.
Statistically significant differences were shown for: i) NM0127 + subcutaneous water and NM0127 + NalMeth vs both intranasal water and NM0127 + Nal (* at 30, 60, 120 min), ii)
NM0127 + subcutaneous water vs intranasal water (** at 120 min), and iii) intranasal water vs all treatment groups (* at 180 min).
The development of analgesic tolerance was assessed by comparing the anti-hyperalgesic response to the first administration of the formulations on Day One (c) and on Day Five following
4 days of twice daily administration of the formulations (d).
c) On Day One statistically significant differences were shown between the subcutaneous morphine (7.5 mg kg−1) vs the vehicle #1 (subcutaneous phosphate buffered saline, PBS,
pH = 7.4) and vehicle #2 (intranasal PBS) groups (* at 15, 30, 60 min) and between the intranasal NM0127 (7.5 mg kg−1) vs vehicle groups (** at 90, 240 min, * at 15, 30, 60, 120,
180 min).
d) On Day Five, animals (dosed on Day 1 and results shown in 3c) that had subsequently been administered formulations twice daily over 4 days – known as pre-treatment formulations
were dosed with new formulations and their responses compared. Intranasal NM0127 was compared after pre-treatment with NM0127 (NM0127 + NM0127) or pre-treatment with
intranasal vehicle (vehicle + NM0127) and these were both compared to subcutaneous morphine after morphine pre-treatment (morphine + morphine) and treatment with only the
subcutaneous vehicle control group (vehicle + vehicle). Statistically significant differences were seen between the following pre-treatment + treatment combinations: vehicle
+ NM0127 vs vehicle + vehicle (** at 20, 60, 90 min; * at 40, 180 min), NM0127 + NM0127 vs vehicle + vehicle (* at 90, 120, 180 min), while morphine + morphine was not
significantly different from vehicle + vehicle.
Cross-tolerance to morphine was also assessed by comparing anti-hyperalgesic responses pre- and post repeat administration as outlined above in Fig. 3c and d.
e) On Day One statistically significant differences were shown between the subcutaneous morphine #1 and morphine #2 groups (7.5 mg kg−1) and the subcutaneous vehicle (PBS) group
(*** at 30 min, ** at 60, 90 min).
f) On Day Five, animals (dosed on Day 1 and results shown in 3e) that had subsequently been administered formulations twice daily over 4 days – known as pre-treatment formulations
were dosed with new formulations and their responses compared. Statistically significant differences were observed between the responses from the morphine (7.5 mg kg−1) + NM0127
(7.5 mg kg−1) and the subcutaneous vehicle + subcutaneous vehicle group (*** at 30 min, ** at 60, 90 min, * at 120 min) or the morphine + NM0127 and morphine + morphine
groups (** at 30, 90 min, * at 60, 120 min). The morphine + morphine group was not significantly different from the vehicle control group.
Assessment of cross tolerance at higher doses was carried out as outlined above and responses on Day One (g) and Day Five (h) are shown.
g) On Day One, statistically significant differences were seen between: i) the vehicle #1 and vehicle #2 (both subcutaneous PBS) groups and the subcutaneous morphine (7.5 mg kg−1)
group (*** at 30, 60 min, ** at 120, 180 min, * at 90 min), ii) the vehicle groups and high dose NM0127 (NM0127-H, 15 mg kg−1 LENK, LENK concentration = 60 mg mL−1, GCPQ,
LENK ratio = 1: 1 g g−1) group (** at 60 min, * 30, 90, 120, 180 min), iii) the vehicle groups and NM0127 (7.5 mg kg−1) group (*** at 180 min, ** 120 min, * 30, 60, 90 min) and iv)
the NM0127 and subcutaneous morphine groups (# = p < 0.05 at 60 min).
h) On Day Five, animals (dosed on Day 1 and results shown in 3 g) that had subsequently been administered formulations twice daily over 4 days – known as pre-treatment formulations
were dosed with new formulations and their responses compared. Statistically significant differences were seen between: i) the subcutaneous vehicle control groups (vehicle + vehicle)
and the vehicle + NM0127-H group (** at 90 min, * at 60, 120, 240 min), ii) the vehicle + vehicle group and the NM0127-H + NM0127-H group (*** at 120 min, ** at 180, 240 min, *
at 60, 90 min), iii) the vehicle + vehicle group and the NM0127 + NM0127 (both at 7.5 mg kg−1) groups (** at 60 min, * at 120 min), iv) the vehicle + vehicle and the morphine
+ NM0127-H group (** at 60, 120, 180 min, * at 90 min), v) the morphine + NM0127-H and the vehicle + NM0127-H groups (* at 90 min), and vi) the morphine + NM0127-H and the
NM0127-H + NM0127-H groups (** at 120 min).
i) The effect of NM0127 against spontaneous pain in nerve injured rats (n = 13–18) was assessed in a conditioned placement preference model. The time spent in the drug paired chamber
(red bars) and vehicle paired chamber (blue bars) did not differ at baseline, following sham treatment not involving spinal ligation (p > 0.05) and following spinal nerve ligation (SNL,
p > 0.05). Therefore data were pooled for graphical representation. Following single trial conditioning with morning treatment with intranasal vehicle (0.25 mL kg−1) and afternoon
treatment 4 h later with intranasal NM0127 (GCPQ, LENK ratio = 1 g g−1) at a LENK dose of 15 mg kg−1 (60 mg mL−1) there was a statistically significant increase in the time spent in
the NM0127 paired chamber selectively with SNL but not sham treated rats.
j) Comparison of the difference score (time in drug chamber at baseline – time in drug chamber following treatment) for both sham and SNL animals (n = 13–18) confirm that SNL treated
rats show a significant increase in the time spent in the NM0127 paired chamber when compared to sham treated rats. * = Statistically significantly different when compared to sham
treated rats (p < 0.05).
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significant advantages over the current MOR agonists. Approximately
40–95% of MOR agonist patients develop constipation [11], which is
largely peripherally mediated [41] and as such peripherally restricted
MOR antagonists have been developed to control the constipation side
effect [42]. The centrally restricted activity of NM0127 has a good
probability of addressing this major side effect.
Analgesic tolerance is a major side effect of MOR agonist use: 1 in
12 admissions in a Boston hospital study were patients tolerant to
opioids and opioid tolerance was associated with a longer hospital stay
in these patients [43]. Opioid tolerance is known to be very difficult to
manage [44]. Our data demonstrate that analgesic tolerance does not
develop to NM0127 (Fig. 3c and d) and that NM0127 is active in
morphine tolerant animals (Fig. 3e–h). Additionally chronic morphine
dosing produced immediate hyperactivity post dosing, with hyper-
activity beginning 2 min after dosing on Day 4, and such hyperactivity
was not observed in the NM0127 dosed animals (data not shown). The
molecular mechanisms of opioid analgesic tolerance are poorly under-
stood [45,46] and future studies will seek to understand the lack of
analgesic tolerance shown by NM0127.
Finally we show for the first time that intranasal LENK nanoparticles
induce conditioned placement preference selectively in animals, with
spinal nerve ligation injury, suggesting blockade of on going neuro-
pathic pain (Fig. 3i and j). It should be noted that animals with sham
surgery do not show place conditioning to NM0127, suggesting no to
minimal reward seeking behaviour after a single intranasal dose of
NM0127. Further experiments with validated addiction models are re-
quired for this lack of reward seeking behaviour to be confirmed.
4. Conclusions
In summary, we introduce nanotechnology, with accompanying
short term stability data, which has the potential to be scaled up into a
pharmaceutical product, using industrially relevant equipment and
processes (high pressure homogenisation and spray drying). The na-
notechnology enables the exclusive delivery of a metabolically labile
peptide drug into the brain on intranasal delivery. Unexpected phar-
macological evidence of activity of the delta selective opioid agonist
(LENK) in morphine tolerant animals was also uncovered. We also
provide evidence that these nanoparticles may be presented as a mi-
croparticle based powder to satisfy regulatory requirements and that
the nanoparticle polymer is well tolerated via the nasal route at the
dose administered.
Acknowledgements
Charles River, Edinburgh, UK is acknowledged for the conduct of
the conduct of the GCPQ nanoparticles GLP repeat dose toxicology
studies.
The UK Engineering and Physical Sciences Research Council(EP/
K502340/1), Nanomerics Ltd.(NM12TSB-NPP) and Innovate UK
(16939-124181) are acknowledged for funding.
Author contributions
Ijeoma F. Uchegbu, Andreas G. Schätzlein, Lisa Godfrey, Tamara
King, Frank Porreca, Antonio Iannitelli, Julian Moger and Natalie
Garrett conceived and designed the experiments. Ijeoma Uchegbu and
Lisa Godfrey wrote the manuscript and analysed the data. Lisa Godfrey,
Tamara King, Antonio Iannitelli, Natalie Garrett, Aikaterini Lalatsa, Ian
Imbert and Ramesh Soundararajan performed the experiments and
analysed the data. All authors reviewed the manuscript prior to pub-
lication.
Appendix A. Supplementary data
Supporting information contains stability data on NM0127 and data
from the safety studies on the self-assembling nanoparticle forming
polymer. Supplementary data associated with this article can be found
in the online version, at https://doi.org/10.1016/j.jconrel.2017.11.
041.
References
[1] M. Mazza, R. Notman, J. Anwar, A. Rodger, M. Hicks, G. Parkinson, D. McCarthy,
T. Daviter, J. Moger, N. Garrett, T. Mead, M. Briggs, A.G. Schatzlein, I.F. Uchegbu,
Nanofiber-based delivery of therapeutic peptides to the brain, ACS Nano 7 (2013)
1016–1026.
[2] C.D. Chapman, W.H. Frey II, S. Craft, L. Danielyan, M. Hallschmid, H.B. Schioth,
C. Benedict, Intranasal treatment of central nervous system dysfunction in humans,
Pharm. Res. 30 (2013) 2475–2484.
[3] M.A. Hussain, S.M. Rowe, A.B. Shenvi, B.J. Aungst, Inhibition of leucine enkephalin
metabolism in rat blood, plasma and tissues in vitro by an aminoboronic acid de-
rivative, Drug Metab. Dispos. 18 (1990) 288–291.
[4] H.W. Kosterlitz, Enkephalins, endorphins and their receptors, in: C.A. Marsen,
W.Z. Traczyk (Eds.), Neuropeptides and Neural Transmission, Raven Press, New
York, 1980.
[5] L. Toll, I.P. Berzetei-Gurske, W.E. Polgar, S.R. Brandt, I.D. Adapa, L. Rodriguez,
R.W. Schwartz, D. Haggart, A. O'Brien, A. White, J.M. Kennedy, K. Craymer,
L. Farrington, J.S. Auh, Standard binding and functional assays related to medica-
tions development division testing for potential cocaine and opiate narcotic treat-
ment medications, NIDA Res. Monogr. 178 (1998) 440–466.
[6] J. Peng, S. Sarkar, S.L. Chang, Opioid receptor expression in human brain and
peripheral tissues using absolute quantitative real-time RT-PCR, Drug Alcohol
Depend. 124 (2012) 223–228.
[7] H. Breivik, B. Collett, V. Ventafridda, R. Cohen, D. Gallacher, Survey of chronic pain
in Europe: prevalence, impact on daily life, and treatment, Eur. J. Pain 10 (2006)
287–333.
[8] S. Nightingale, The neuropathic pain market, Nat. Rev. Drug Discov. 11 (2012)
102–103.
[9] R.K. Portenoy, D.S. Bennett, R. Rauck, S. Simon, D. Taylor, M. Brennan,
S. Shoemaker, Prevalence and characteristics of breakthrough pain in opioid-
treated patients with chronic noncancer pain, J. Pain 7 (2006) 583–591.
[10] G.W. Pasternak, Y.X. Pan, Mu opioids and their receptors: evolution of a concept,
Pharmacol. Rev. 65 (2013) 1257–1317.
[11] R. Benyamin, A.M. Trescot, S. Datta, R. Buenaventura, R. Adlaka, N. Sehgal,
S.E. Glaser, R. Vallejo, Opioid complications and side effects, Pain Physician 11
(2008) S105–120.
[12] G. Roscetti, R. Possenti, E. Bassano, L.G. Roda, Mechanisms of leu-enkephalin hy-
drolysis in human plasma, Neurochem. Res. 10 (1985) 1393–1404.
[13] L. Churchill, H.H. Bausback, M.E. Gerritsen, P.E. Ward, Metabolism of opioid
peptides by cerebral microvascular aminopeptidase M, Biochim. Biophys. Acta 923
(1987) 35–41.
[14] A. Lalatsa, A.G. Schatzlein, I.F. Uchegbu, Strategies to deliver peptide drugs to the
brain, Mol. Pharm. 11 (2014) 1081–1093.
[15] A. Lalatsa, N. Garrett, J. Moger, A.G. Schatzlein, C. Davis, I.F. Uchegbu, Delivery of
peptides to the blood and brain after oral uptake of quaternary ammonium pal-
mitoyl glycol chitosan nanoparticles, Mol. Pharm. 9 (2012) 1764–1774.
[16] A. Lalatsa, V. Lee, J.P. Malkinson, M. Zloh, A.G. Schatzlein, I.F. Uchegbu, A prodrug
nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-
enkephalin, to the brain, Mol. Pharm. 9 (2012) 1665–1680.
[17] B.P. Roques, M.C. Fournie-Zaluski, M. Wurm, Inhibiting the breakdown of en-
dogenous opioids and cannabinoids to alleviate pain, Nat. Rev. Drug Discov. 11
(2012) 292–310.
[18] L. Illum, Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol.
56 (2004) 3–17.
[19] K. Ohkubo, J.N. Baraniuk, M. Merida, J.N. Hausfeld, H. Okada, M.A. Kaliner,
Human nasal mucosal carboxypeptidase: activity, location, and release, J. Allergy
Clin. Immunol. 96 (1995) 924–931.
[20] X. Zhang, Q.Y. Zhang, D. Liu, T. Su, Y. Weng, G. Ling, Y. Chen, J. Gu, B. Schilling,
X. Ding, Expression of cytochrome p450 and other biotransformation genes in fetal
and adult human nasal mucosa, Drug Metab. Dispos. 33 (2005) 1423–1428.
[21] A. Fortuna, G. Alves, A. Serralheiro, J. Sousa, A. Falcao, Intranasal delivery of
systemic-acting drugs: small-molecules and biomacromolecules, Eur. J. Pharm.
Biopharm. 88 (2014) 8–27.
[22] S.T. Charlton, S.S. Davis, L. Illum, Nasal administration of an angiotensin antagonist
in the rat model: effect of bioadhesive formulations on the distribution of drugs to
the systemic and central nervous systems, Int. J. Pharm. 338 (2007) 94–103.
[23] S. Orita, T. Ishikawa, M. Miyagi, N. Ochiai, G. Inoue, Y. Eguchi, H. Kamoda, G. Arai,
T. Toyone, Y. Aoki, T. Kubo, K. Takahashi, S. Ohtori, Pain-related sensory in-
nervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually
develops neuronal injury in addition to inflammatory pain, BMC Musculoskelet.
Disord. 12 (2011) 134.
[24] W.J. Dixon, Efficient analysis of experimental observations, Ann. Rev. Pharmacol.
Toxicol. 20 (1980) 441–462.
[25] S.H. Kim, J.M. Chung, An experimental model for peripheral neuropathy produced
by segmental spinal nerve ligation in the rat, Pain 50 (1992) 355–363.
[26] T. King, L. Vera-Portocarrero, T. Gutierrez, T.W. Vanderah, G. Dussor, J. Lai,
H.L. Fields, F. Porreca, Unmasking the tonic-aversive state in neuropathic pain, Nat.
Neurosci. 12 (2009) 1364–1366.
[27] R. Wang, T. King, M. De Felice, W. Guo, M.H. Ossipov, F. Porreca, Descending
L. Godfrey et al. Journal of Controlled Release 270 (2018) 135–144
143
facilitation maintains long-term spontaneous neuropathic pain, J. pain 14 (2013)
845–853.
[28] N.L. Garrett, A. Lalatsa, I. Uchegbu, A. Schatzlein, J. Moger, Exploring uptake
mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy,
J. Biophotonics 5 (2012) 458–468.
[29] J.D. Belluzzi, N. Grant, V. Garsky, D. Sarantakis, C.D. Wise, L. Stein, Analgesia
induced in vivo by central administration of enkephalin in rat, Nature 260 (1976)
625–626.
[30] European Medicines Agency, Committee for Medicinal Products for Human Use -
Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products, http://
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/
09/WC500003568.pdf, (2006).
[31] J. Moger, N.L. Garrett, D. Begley, L. Mihoreanu, A. Lalatsa, M. Lozano, M. Mazza,
A. Schatzlein, I.F. Uchegbu, Imaging cortical vasculature with stimulated Raman
scattering and two photon photothermal lensing microscopy, J. Raman Spectrosc.
43 (2012) 668–674.
[32] J.J. Lochhead, D.J. Wolak, M.E. Pizzo, R.G. Thorne, Rapid transport within cerebral
perivascular spaces underlies widespread tracer distribution in the brain after in-
tranasal administration, J. Cereb. Blood Flow Metab. 35 (2015) 371–381.
[33] N.J. Johnson, L.R. Hanson, W.H. Frey, Trigeminal pathways deliver a low molecular
weight drug from the nose to the brain and orofacial structures, Mol. Pharm. 7
(2010) 884–893.
[34] N.N. Kumar, M. Gautam, J.J. Lochhead, D.J. Wolak, V. Ithapu, V. Singh,
R.G. Thorne, Relative vascular permeability and vascularity across different regions
of the rat nasal mucosa: implications for nasal physiology and drug delivery, Sci.
Rep. 6 (2016) 31732.
[35] D.R. Serrano, A. Lalatsa, M.A. Dea-Ayuela, P.E. Bilbao-Ramos, N.L. Garrett,
J. Moger, J. Guarro, J. Capilla, M.P. Ballesteros, A.G. Schatzlein, F. Bolas,
J.J. Torrado, I.F. Uchegbu, Oral particle uptake and organ targeting drives the ac-
tivity of amphotericin B nanoparticles, Mol. Pharm. 12 (2015) 420–431.
[36] A.J. Blume, J. Shorr, J.P. Finberg, S. Spector, Binding of the endogenous nonpeptide
morphine-like compound to opiate receptors, Proc. Natl. Acad. Sci. U. S. A. 74
(1977) 4927–4931.
[37] M. Kumar, R.S. Pandey, K.C. Patra, S.K. Jain, M.L. Soni, J.S. Dangi, J. Madan,
Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to
brain delivery, Int. J. Biol. Macromol. 61 (2013) 189–195.
[38] A. Siew, H. Le, M. Thiovolet, P. Gellert, A. Schatzlein, I. Uchegbu, Enhanced oral
absorption of hydrophobic and hydrophilic drugs using quaternary ammonium
palmitoyl glycol chitosan nanoparticles, Mol. Pharm. 9 (2012) 14–28.
[39] W.T. Chance, J.L. Nelson, Antagonism of stress-induced analgesia by quaternary
naloxone, Brain Res. 380 (1986) 394–396.
[40] S.H. Ngai, B.A. Berkowitz, J.C. Yang, J. Hempstead, S. Spector, Pharmacokinetics of
naloxone in rats and in man: basis for its potency and short duration of action,
Anesthesiology 44 (1976) 398–401.
[41] T. Mori, Y. Shibasaki, K. Matsumoto, M. Shibasaki, M. Hasegawa, E. Wang,
D. Masukawa, K. Yoshizawa, S. Horie, T. Suzuki, Mechanisms that underlie mu-
opioid receptor agonist-induced constipation: differential involvement of mu-opioid
receptor sites and responsible regions, J. Pharmacol. Exp. Ther. 347 (2013) 91–99.
[42] J.A. Cassel, J.D. Daubert, R.N. DeHaven, H-3 alvimopan binding to the mu opioid
receptor: comparative binding kinetics of opioid antagonists, Eur. J. Pharmacol.
520 (2005) 29–36.
[43] P. Gulur, L. Williams, S. Chaudhary, K. Koury, M. Jaff, Opioid tolerance—a pre-
dictor of increased length of stay and higher readmission rates, Pain Physician 17
(2014) E503–507.
[44] J.L. Wilson, P.A. Poulin, R. Sikorski, H.J. Nathan, M. Taljaard, C. Smyth, Opioid use
among same-day surgery patients: prevalence, management and outcomes, Pain
Res. Manag. 20 (2015) 300–304.
[45] R. Al-Hasani, M.R. Bruchas, Molecular mechanisms of opioid receptor-dependent
signaling and behavior, Anesthesiology 115 (2011) 1363–1381.
[46] A.A. Pradhan, W. Walwyn, C. Nozaki, D. Filliol, E. Erbs, A. Matifas, C. Evans,
B.L. Kieffer, Ligand-directed trafficking of the delta-opioid receptor in vivo: two
paths toward analgesic tolerance, J. Neurosci. 30 (2010) 16459–16468.
L. Godfrey et al. Journal of Controlled Release 270 (2018) 135–144
144
